GSK plc (GSK) Stock Analysis

GSK’s competitive edge rests on a combination of scale, portfolio breadth, R&D productivity, and operational discipline. The company is a global leader in vaccines and specialty medicines, with 2025 sales of £32.7 billion and a gross margin of 72%. Its vaccines business, including Shingrix (shingles) and Arexvy (RSV), benefits from high barriers to entry due to complex manufacturing and regulatory requirements. In HIV, GSK’s ViiV Healthcare unit holds a leading position, with long-acting injectables (Cabenuva, Apretude) now accounting for over 75% of HIV growth—outpacing Gilead and Johnson & Johnson in this segment.

GSK’s R&D pipeline is robust, with 58 assets in development and over half sourced through business development, reflecting a disciplined approach to external innovation. The company’s focus on immune system science and advanced technologies (e.g., AI-driven drug discovery) has accelerated pipeline delivery and improved trial efficiency. Compared to peers like Pfizer and Sanofi, GSK’s pipeline is more concentrated in respiratory, immunology, and infectious diseases, where it has established expertise.

Operationally, GSK’s cost discipline is evident in its 2025 core operating margin of 30% and a progressive dividend policy. The company’s culture emphasizes responsible business practices and access, ranking second in the Access to Medicines Index. Risks include pricing pressure, patent expiries, and intensifying competition, but GSK’s diversified portfolio and innovation engine provide resilience relative to most large-cap pharma peers.